Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


20 Items
Title  Creator  Group name  Publishing year 
Assessing Histology Structures by Ex Vivo MR Microscopy and Exploring the Link Between MRM-Derived Radiomic Features and Histopathology in Ovarian Cancer Tardieu et al. EquipeCTCS 2021
Radiomics: an Introductory Guide to What It May Foretell Nougaret et al. EquipeMY 06 25, 2019
MRI of Tumors and Tumor Mimics in the Female Pelvis: Anatomic Pelvic Space-based Approach Nougaret et al. EquipeMY 2019 Jul-Aug
Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? Himoto et al. EquipeMY 11 2019
Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer Himoto et al. EquipeMY 2019
Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer Meier et al. EquipeMY 06 2019
Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology Nougaret et al. EquipeMY Jul 11, 2018
CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas Nougaret et al. EquipeMY Apr 2018
The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer Nougaret et al. EquipeMY 07 2017
High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes Nougaret et al. EquipeMY 11 2017
From Staging to Prognostication: Achievements and Challenges of MR Imaging in the Assessment of Endometrial Cancer Nougaret et al. EquipeMY Aug 2017
Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management McEvoy et al. EquipeMY 10 2017
Erratum to: Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management McEvoy et al. EquipeMY 12 2017
Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis Lakhman et al. EquipeMY Jul 2017
A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome Vargas et al. EquipeMY Sep 2017
The Wheel of the Mesentery: Imaging Spectrum of Primary and Secondary Mesenteric Neoplasms--How Can Radiologists Help Plan Treatment?: Resident and Fellow Education Feature Nougaret et al. EquipeMY 2016 Mar-Apr
Second-Opinion Interpretations of Gynecologic Oncologic MRI Examinations by Sub-Specialized Radiologists Influence Patient Care Lakhman et al. EquipeMY Jul 2016
Response Nougaret et al. EquipeMY Apr 2016
Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies Lakhman et al. EquipeMY 2015 Jul-Aug
Endometrial Cancer: Combined MR Volumetry and Diffusion-weighted Imaging for Assessment of Myometrial and Lymphovascular Invasion and Tumor Grade Nougaret et al. EquipeMY Sep 2015
20 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés